EBR Systems Locks in 3-Year Deal Across 66-Hospital U.S. Network
EBR Systems expands U.S. hospital reach with CHRISTUS Health purchasing agreement
EBR Systems (ASX: EBR) has secured a three-year purchasing agreement with CHRISTUS Health, the ninth-largest hospital network in the United States. The agreement establishes a procurement pathway for the WiSE CRT System across a network of 66 hospitals, 600+ centres, and more than 45,000 team members, including 15,000 clinicians, concentrated primarily across Texas, Louisiana, and New Mexico.
The agreement marks a further step in EBR’s ongoing U.S. commercial rollout, broadening institutional access to the WiSE CRT System across one of the country’s largest faith-based, mission-driven health systems.
John McCutcheon, President & Chief Executive Officer
“We are pleased to establish a purchasing agreement with CHRISTUS Health, an organization recognized for its commitment to patient-centered care. This agreement helps broaden institutional access to the WiSE CRT System and supports our ongoing efforts to bring leadless CRT therapy to more patients across the U.S.”
When big ASX news breaks, our subscribers know first
What the WiSE CRT System does and why leadless pacing matters
Cardiac resynchronisation therapy (CRT) is a treatment for heart failure patients whose left ventricle requires electrical stimulation to beat in proper synchrony with the rest of the heart. In conventional CRT, this is achieved via a coronary sinus lead, a pacing wire positioned on the outside of the left ventricle. That external lead has historically been a source of complications, reliability issues, and procedural difficulty.
EBR’s WiSE technology addresses this by delivering wireless, endocardial stimulation directly from inside the left ventricle. The implant is roughly the size of a large grain of rice, eliminating the need for the external lead entirely.
Key technology points at a glance:
- Wireless endocardial stimulation of the left ventricle
- Implant approximately the size of a large grain of rice
- Eliminates coronary sinus lead and associated complications
- World’s only device of its kind in clinical use
WiSE is currently only available for commercial sale in the U.S. and remains an investigational device in most other markets. With the CHRISTUS agreement now in place, EBR’s sales representatives can engage directly with physicians across suitable CHRISTUS locations, expanding the pool of hospitals where the company can bring WiSE to eligible patients.
Inside the CHRISTUS Health agreement and what it means for EBR’s rollout
In practical terms, a purchasing agreement establishes a pre-approved procurement pathway within a hospital network. This allows EBR sales representatives to engage directly with individual CHRISTUS Health physicians at suitable hospital locations, bypassing the need for hospital-by-hospital contracting from scratch. The agreement has a duration of three years.
The scale of the CHRISTUS network gives this arrangement meaningful reach. With 66 hospitals spread across Texas, Louisiana, and New Mexico, the agreement provides access across a geographically concentrated and institutionally cohesive health system. Over time, the arrangement is expected to support broader hospital access as the U.S. commercial rollout continues, though no volume commitments or revenue figures have been disclosed.
| Network Stat | Figure | Relevance to EBR |
|---|---|---|
| Hospital network rank | 9th largest in the U.S. | Establishes CHRISTUS as a major institutional counterparty |
| Total centres | 600+ | Broad footprint across which procurement pathway now applies |
| Hospitals | 66 | Direct sites for physician-level engagement by EBR sales reps |
| Clinicians | 15,000 | Addressable physician base for WiSE CRT referrals and procedures |
| Primary geography | Texas, Louisiana, New Mexico | Concentrated market presence supporting focused commercial activity |
The next major ASX story will hit our subscribers first
Building the commercial foundation: EBR’s U.S. rollout trajectory
Hospital network agreements are a foundational element of commercialising a novel medical device in the U.S. market. By securing a pre-approved purchasing pathway at the network level, EBR removes a material barrier to physician-level engagement, allowing its sales team to focus on clinical conversations and procedure adoption rather than procurement negotiations at each individual site.
Because WiSE is currently only available for commercial sale in the U.S., every new hospital network agreement represents a direct addition to the company’s addressable commercial footprint. The CHRISTUS partnership supports EBR’s stated objective of bringing leadless CRT therapy to more patients across the country.
For investors tracking the pace of the U.S. rollout, the key metrics to watch are:
- Physician engagement activity across CHRISTUS Health hospitals
- Procedure volume growth within the network over the three-year term
- Additional hospital network agreements as the broader U.S. commercial rollout continues
No financial terms, volume commitments, or revenue projections have been disclosed in connection with the CHRISTUS agreement. The pace of physician engagement and procedure uptake across the network will be the indicator of commercial traction as the partnership develops.
Don’t Miss the Next Healthcare Breakout on the ASX
Big News Blast delivers FREE breaking ASX healthcare news straight to your inbox within minutes of release, complete with in-depth analysis. Over 20,000+ subscribers are already getting the edge on market-moving announcements the moment they drop. Click the “Free Alerts” button to start receiving alerts before the broader market has time to react.